Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available
June 08 2017 - 9:17AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company
developing cancer immunotherapies, announced that Daniel J.
O’Connor, President and Chief Executive Officer of Advaxis,
presented a company overview today at the Jefferies 2017 Global
Healthcare Conference in New York, NY.
An archived webcast of the presentation is available at
http://wsw.com/webcast/jeff105/adxs.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a biotechnology
company developing multiple cancer immunotherapies based on its
proprietary Lm Technology™. Lm Technology, using
bioengineered live attenuated Listeria monocytogenes (Lm)
bacteria, is the only known cancer immunotherapy agent shown in
preclinical studies to both generate cancer fighting T cells
directed against cancer antigens and neutralize Tregs and
myeloid-derived suppressor cells (MDSCs) that protect the tumor
microenvironment from immunologic attack and contribute to tumor
growth. Advaxis' lead Lm Technology immunotherapy,
axalimogene filolisbac, targets HPV-associated cancers and is
currently has multiple clinical trials underway, including Phase 3
in invasive cervical cancer, Phase 2 in head and neck cancer, and
Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac
orphan drug designation for each of these three clinical settings,
as well as Fast Track designation for adjuvant therapy for
high-risk, locally advanced cervical cancer (HRLACC) patients and a
Special Protocol Assessment agreement for the Phase 3 AIM2CERV
trial in HRLACC patients. Axalimogene filolisbac has also been
classified as an advanced therapy medicinal product for the
treatment of cervical cancer by the European Medicines Agency’s
Committee for Advanced Therapies. Advaxis has two additional
immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2
in HER2 expressing solid tumors, in human clinical development. In
addition, Advaxis and Amgen are developing ADXS-NEO, an
investigational cancer immunotherapy treatment designed to activate
a patient's immune system to respond against the unique mutations,
or neoepitopes, contained in and identified from each individual
patient's tumor, with plans to enter the clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop the next generation of cancer immunotherapies,
and the safety and efficacy of Advaxis’ proprietary immunotherapy,
axalimogene filolisbac. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170608005702/en/
Advaxis, Inc.Noelle Heber, 609-250-7575Sr. Director Corporate
Communications and Government Affairsheber@advaxis.comorMedia
Contact:JPA Health CommunicationsDavid Connolly,
617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024